Veness Adam M 4

4 · Dianthus Therapeutics, Inc. /DE/ · Filed Jun 18, 2026

AI-generated summary of this filing

Updated Jun 18, 2026

Dianthus (DNTH) SVP Adam Veness Exercises Options, Sells Shares

What Happened

Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics (DNTH), exercised stock options to acquire 30,000 shares on 2026-06-17 at $17.88 per share for a cost of $536,400. On the same day he sold a total of 30,000 shares in two open-market transactions, receiving aggregate proceeds of approximately $2,423,958.
Sales details: 16,771 shares disposed at a weighted average price of $80.34 (range $80.00–$80.99) for $1,347,382, and 13,229 shares disposed at a weighted average price of $81.38 (range $81.00–$81.80) for $1,076,576. The filing also shows a separate derivative disposition of 30,000 shares at $0.00 (reported as a derivative transaction).

Key Details

Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (timely filing).
Options exercised: 30,000 shares @ $17.88 (total cash paid $536,400).
Shares sold: 30,000 total (16,771 and 13,229) for about $2.42M combined (weighted-average prices reported; see footnotes for price ranges).
Notable footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted March 18, 2026. The reported sale prices are weighted averages across multiple executions (ranges provided in the filing). Vesting schedule note: related option award vests monthly over four years from Jan 1, 2024.
Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

This filing shows an option exercise paired with same-day open-market sales. That pattern can reflect a planned exercise-and-sell (or settlement/withholding) rather than an ongoing trading decision; here the sales were executed under a pre-established 10b5-1 plan.
The separate derivative disposition reported at $0.00 may reflect internal option/settlement mechanics reported on the Form 4; the filing does not explain motivations. All facts above are from the Form 4 filings and accompanying footnotes.

Form 4

Period: 2026-06-17

SVP, General Counsel and Sec.

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-17$17.88/sh+30,000$536,400→ 30,000 total
Sale
Common Stock
[F1][F2]
2026-06-17$80.34/sh−16,771$1,347,382→ 13,229 total
Sale
Common Stock
[F1][F3]
2026-06-17$81.38/sh−13,229$1,076,576→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-17−30,000→ 80,000 total
Exercise: $17.88Exp: 2034-01-23→ Common Stock (30,000 underlying)

Footnotes (4)

[F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
[F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
[F4]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Signature

/s/ Adam Veness|2026-06-18

1 file